Anyone taking Ozempic, Mounjaro, or Wegovy might be accidentally lowering their breast cancer risk. A cohort study of over 111,000 women from the University of Pennsylvania, presented at the American Society of Clinical Oncology's annual congress in June 2026, shows a 30 percent lower breast cancer rate among GLP-1 users. The effect remains even after accounting for weight loss, raising the question: do these drugs work directly against cancer?
What the Penn study measured
Elizabeth McDonald, a professor of radiology at the University of Pennsylvania's Perelman School of Medicine, analyzed electronic health records from the Penn health system. The dataset includes 217,624 women who underwent breast imaging between January 2022 and June 2025. For the core analysis, 111,646 women ages 45 to 80 with a BMI of at least 25 (overweight or obese).
Some of this group had taken GLP-1 medications such as semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro), others had not. After accounting for other risk factors, GLP-1 users had about 30 percent lower breast cancer incidence, particularly for hormone-receptor-positive, HER2-negative types. The results were published in JCO Oncology Practice.
The study is retrospective and observational. This means no random assignment and no direct proof of causation. McDonald and her team explicitly noted this and call for prospective studies to confirm the findings.
Why fatty tissue promotes breast cancer
The biological basis for this finding is well documented. Overweight and breast cancer are linked through three mechanisms.
First, estrogen: fatty tissue contains the enzyme aromatase, which converts androgens to estrogen. More fat mass means more estrogen in the blood, and estrogen-receptor-positive tumors require this hormone to grow.
Second, insulin: obesity and type-2 diabetes often come with hyperinsulinemia. Chronically elevated insulin levels activate the IGF-1 signaling pathway, which prompts cancer cells to divide and survive.
Third, inflammation: dysfunctional fat tissue releases inflammatory molecules called adipokines, which activate further cancer-promoting signaling pathways. GLP-1 medications demonstrably reduce insulin resistance and inflammation markers in fat tissue. They may also work through direct GLP-1 receptors in breast tissue. The fact that the protective effect in the Penn study remained after weight adjustment points to exactly these direct mechanisms.
The 30-percent figure and its limits
Shilpa Bhupathiraju, an epidemiologist at Harvard T.H. Chan School of Public Health, highlighted a key concern during the ASCO press discussion: healthcare engagement bias. Anyone taking GLP-1 drugs by definition has access to a doctor and a prescription. These women may go for cancer screening more often and have generally healthier healthcare-seeking behavior. This could lower breast cancer detection rates regardless of the medication itself.
Add to this a warning for a specific subgroup: triple-negative breast cancer, the most aggressive variant without hormone receptors or HER2 receptors, may respond differently. A laboratory study published in early 2026 shows that GLP-1 substances can activate survival pathways in this tumor type and impair the effectiveness of chemotherapy and immunotherapy. The American College of Radiology explicitly flagged this limitation. For women with triple-negative breast cancer or correspondingly high risk, caution would be warranted.
In comparison: what other cancer prevention data shows
Globally, breast cancer incidence varies by country and population. The hormone-receptor-positive type, for which the Penn study shows the strongest protective effect, is the most common form.
By comparison, tamoxifen is already prescribed prophylactically for high-risk groups. The NSABP-P-1 study of over 13,000 women showed a risk reduction for invasive breast cancer of roughly 50 percent. This data comes from a randomized, controlled design with decades of follow-up. For GLP-1 as a preventive, such evidence is still entirely lacking.
The decisive difference lies elsewhere: GLP-1 medications are already prescribed millions of times against obesity and type-2 diabetes. If prospective studies confirm the effect, ongoing therapy could simultaneously provide cancer prevention without requiring an additional medication. That would be clinically and economically significant.
Three conditions until clinical recommendation
For the observation to become a treatment recommendation, three prerequisites must be met.
First, prospective studies must replicate the effect. McDonald is already working on a multicenter clinical trial targeting high-risk groups. Results are expected no earlier than the late 2020s.
Second, the question about triple-negative breast cancer must be clarified. If GLP-1 protects against hormone-receptor-positive cancer but worsens therapy outcomes for this type, any recommendation needs precise subgroup differentiation by tumor biology.
Third, a new indication requires approval from the European Medicines Agency before national health insurance could cover the cost. GLP-1 medications are approved for obesity and type-2 diabetes in Europe, not as a cancer preventive. This regulatory path typically takes several years. Those already taking the drugs might already be benefiting without knowing it.